Vaccine development for hepatitis C

Seminars in Liver Disease

Volumn 20, Issue 2, 2000, Pages 211-226

  Lechmann, M ^a   Jake Liang, T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antibody; Cytotoxic T cell; Immune response; Protective immunity; Recombinant subunit vaccine; T helper cell

Indexed keywords

DNA VACCINE; HEPATITIS C VACCINE;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; PRIORITY JOURNAL; TECHNOLOGY; VACCINATION;

EID: 0033868504     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9947     Document Type: Article

References (125)

1. Advances in vaccine adjuvants
2. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses
3. Dengue virus premembrane and membrane proteins elicit a protective immune response
4. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection
5. Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model
6. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
7. Binding of hepatitis C virus to CD81
8. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
9. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
10. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
11. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection
12. Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response
13. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus
14. Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection
15. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C
16. Absence of anti-envelope antibodies and clearance of hepatitis C virus in a cohort of Irish women infected in 1977
17. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans
18. Strategies and prospects for vaccination against the hepatitis C viruses
19. Limited humoral immunity in hepatitis C virus infection
20. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
21. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
22. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
23. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus - Positive blood donors without viremia
24. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia
25. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
26. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: Implications for vaccine development
27. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
28. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
29. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients
30. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C
31. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes
32. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C [In Process Citation]
33. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
34. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection
35. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis
36. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
37. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
38. Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B*3501 in acute hepatitis
39. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
40. Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein
41. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
42. A minimal and optimal cytotoxic T cell epitope within hepatitis C virus nucleoprotein
43. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
44. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
45. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
46. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
47. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
48. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
49. Analysis of a successful immune response against hepatitis C virus
50. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin
51. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up
52. Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children
53. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells
54. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus
55. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo
56. Transmission of hepatitis C virus infection to tree shrews
57. Heterologous protection against influenza by injection of DNA encoding a viral protein
58. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine
59. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
60. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
61. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge
62. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids
63. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs
64. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid
65. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization
66. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs
67. Flaviviridae: The viruses and their replication
68. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface
69. DNA immunization of macaques and chimpanzees with plasmids encoding hepatitis C virus (HCV) envelope E2 protein
70. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colonystimulating factor gene
71. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice
72. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode
73. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes
74. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model
75. Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization
76. Immune responses to plasmid DNA encoding the hepatitis C virus core protein
77. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses
78. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: Comparative studies of antibody and T-helper responses following genetic immunization
79. Comparison between cytomegalovirus promoter and elongation factor-1 alpha promoter-driven constructs in the establishment of cell lines expressing hepatitis C virus core protein
80. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model
81. Plasmid DNA-based immunization for hepatitis C virus structural proteins: Immune responses in mice
82. A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-alpha promoter elicits HCV-specific cytotoxic T-lymphocytes (CTL)
83. Immune responses to hepatitis C virus structural and nonstrucrural proteins induced by plasmid DNA immunizations [In Process Citation]
84. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
85. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization
86. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1
87. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
88. High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: Protection elicited in a murine model
89. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B
90. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: Induction of an MHC-1-restricted CTL response and protection in a murine model
91. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus
92. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus
93. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: The role of nitric oxide
94. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans
95. Suppression of host immune responses by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence
96. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC
97. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates
98. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge
99. Alphavirus-based expression vectors: Strategies and applications
100. Two-helper RNA system for production of recombinant Semliki forest virus particles
101. Recent advances with recombinant bacterial vaccine vectors
102. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines
103. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus
104. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses
105. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions
106. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees
107. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits
108. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants
109. The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence [In Process Citation]
110. Vaccination of chimpanzees against infection by the hepatitis C virus
111. 1332therapeutic vaccination of chronically infected chimpanzees with the HCV E1 protein
112. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
113. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: Evidence for homologous and partial heterologous protection
114. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection
115. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection
116. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
117. Induction of HPV 16 capsid protein-specific human T cell responses by virus-like particles
118. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: Implications on HIV vaccine development
119. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells
120. Hepatitis C Virus-like Particles Synthesized in Insect Cells as a Potential Vaccine Candidate
121. Induction of humoral and cellular immune responses in mice by immunization with insect-cell derived HCV-like particles
122. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
123. Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees - Trials of experimental immune treatment
124. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
125. Neutralizing antibody-independent containment of immunodeficiency virus